<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529850</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4419-202</org_study_id>
    <nct_id>NCT04529850</nct_id>
  </id_info>
  <brief_title>Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer</brief_title>
  <official_title>An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 when administered IV in&#xD;
      combination with IMRT/cisplatin to up to 70 subjects with head and neck cancer, who are at&#xD;
      high risk for SOM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive 90 mg GC4419 per day (60 min IV infusion to complete within 60 minutes&#xD;
      prior to IMRT), concurrent with daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy&#xD;
      over approximately 7 weeks, plus cisplatin administered 100 mg/m2 once every three weeks for&#xD;
      3 doses or 40 mg/m2 once weekly for 6-7 doses (Investigator's choice).&#xD;
&#xD;
      All subjects will be assessed twice weekly for OM per WHO grading criteria until 28 days post&#xD;
      end of study treatment period (last day of IMRT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>to evaluate the effects of GC4419 in subjects with head and neck cancer, who are at high risk for SOM</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent AE's</measure>
    <time_frame>First treatment through 28 days post last dose of GC4419</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Severe OM</measure>
    <time_frame>First treatment through 28 days post last dose of GC4419</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Open Label Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90mg GC4419 by IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: GC4419</intervention_name>
    <description>GC4419 60 Minute Infusion</description>
    <arm_group_label>Open Label Active Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically-confirmed diagnosis of locally advanced squamous cell carcinoma of the&#xD;
             head and neck that will be treated with cisplatin plus concurrent IMRT.&#xD;
&#xD;
          2. Treatment plan to receive a continuous course of IMRT delivered as single daily&#xD;
             fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy.&#xD;
&#xD;
          3. Patients who have had prior surgery may be eligible,&#xD;
&#xD;
          4. Treatment plan to receive standard cisplatin monotherapy administered either every&#xD;
             three weeks (100 mg/m2 for 3 doses) or weekly (40 mg/m2 for 6-7 doses).&#xD;
&#xD;
          5. Age 18 years or older&#xD;
&#xD;
          6. ECOG performance status ≤ 2&#xD;
&#xD;
          7. Adequate hematologic function&#xD;
&#xD;
          8. Adequate renal and liver function Alkaline phosphatase ≤ 2.5 ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic disease&#xD;
&#xD;
          2. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites&#xD;
&#xD;
          3. Prior induction chemotherapy or plans for chemotherapy to be administered only&#xD;
             sequentially with IMRT&#xD;
&#xD;
          4. Planned concurrent chemotherapy other than single agent cisplatin&#xD;
&#xD;
          5. Receiving any approved or investigational anti-cancer agent&#xD;
&#xD;
          6. Concurrent participation in another interventional clinical study&#xD;
&#xD;
          7. Inability to eat soft solid food at baseline for reasons other than mouth soreness&#xD;
             after surgery or dental procedures&#xD;
&#xD;
          8. Complete reliance on parenteral or gastrointestinal tube-delivered nutrition at&#xD;
             baseline&#xD;
&#xD;
          9. Malignant tumors other than head and neck cancer (HNC) within the last 5 years&#xD;
&#xD;
         10. Active infectious disease excluding oral candidiasis&#xD;
&#xD;
         11. Presence of oral mucositis at baseline.&#xD;
&#xD;
         12. Known history of human immunodeficiency virus (HIV) or active hepatitis B/C&#xD;
&#xD;
         13. Female patients who are pregnant or breastfeeding&#xD;
&#xD;
         14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds&#xD;
&#xD;
         15. Requirement for concurrent treatment with nitrates or other drugs that may, in the&#xD;
             judgment of the treating Investigator, create a risk for a precipitous decrease in&#xD;
             blood pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Verviers</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Na Bulovce</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig AoR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o.</name>
      <address>
        <city>Pomorskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario De Santiago De Compostela</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gurutzetako Unibersitate Ospitalea - Hospital Universitario Cruces - Instituto BioCruces</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Universitario Sanchinarro (Centro Integral Oncologico Clara Campal)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra (CHN)</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Virgen del Rocio</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Salamanca - Hospital Clinico Universitario</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bern, Inselspital</name>
      <address>
        <city>Freiburg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avasopasem manganese</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

